Natural History in Children up to 16 Years With Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Necker HospitalParis, FranceContact: Lionel HOVSEPIAN, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sensorion
- Trial code
- NCT05402813
- Record updated
- 1 June 2026
- Original description
The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 16 years of age.Read full original descriptionShow less
Longitudinal Study of the Natural History of Two Autosomal Recessive Non Syndromic Deafness (DFNB1A and DFNB9) in Children up to 16 Years of Age
The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 16 years of age.
Exclusion: Other type of deafness, such as unilateral deafness, persistent conductive deafness, malformation syndrome, syndromic deafness, known familial deafness linked to mutations in other genes than OTOF or GJB2; Participants presenting with any of the following main exclusion criteria will not be included in the study; Documented genotyping results showing pathogenic mutation(s) in other gene(s) than GJB2 or OTOF genes in the tested panel; Unable and/or unwilling to comply with all the protocol requirements and/or study procedures.
Main Inclusion Criteria:; Participants meeting all the following main inclusion criteria will be eligible to participate in the study:; Aged ≤ 16 years on the date of signed informed consent for cohort 1 and ≤ 10 years for cohort 2; With a diagnosis of non-syndromic, bilateral, mild to profound, sensorineural hearing loss (according to the American Speech Language-Hearing Association); With documented genotyping results showing mutation(s) in GJB2 or OTOF genes; Written informed consent as required by local regulations; Either without Cochlear Implant, or with unilateral or bilateral Cochlear Implant(s).